Northbrook

Researchers are evaluating the effectiveness of satralizumab compared to a placebo in treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD). This Phase III study focuses on the time from randomization to the first confirmed MOGAD relapse during the double-blind treatment period. Participants who experience a relapse or complete the double-blind phase may continue into an open-label extension period, with additional adolescents possibly joining the extension after the primary clinical cutoff. The study involves administering satralizumab or placebo by subcutaneous injection in the abdominal or femoral area during site visits after completing other study procedures. Treatment is given as either monotherapy or alongside baseline therapy. Participants remain in the double-blind phase until relapse or study completion, after which they may enter the open-label extension to continue receiving satralizumab. During the study, participants undergo regular assessments to monitor for relapses, including evaluations by an adjudication committee. Researchers measure the time to first MOGAD relapse while also monitoring safety, pharmacokinetics, and pharmacodynamics. The study includes ongoing follow-up and safety monitoring for up to approximately 44 months from randomization, ensuring comprehensive evaluation of the treatment's impact.

Researchers are evaluating the safety and effectiveness of ARTIA Reconstructive Tissue Matrix in adult women undergoing immediate, two-stage, implant-based breast reconstruction after mastectomy. This study focuses on using ARTIA in pre-pectoral breast reconstruction and compares it to patients who receive no acellular dermal matrix (ADM). The research is a Phase 3, prospective, multicenter, open-label, controlled pivotal study designed to assess outcomes following breast reconstruction surgery. Participants will undergo either unilateral or bilateral mastectomy and receive immediate two-stage breast reconstruction either with the ARTIA device or without ADM. The ARTIA Reconstructive Tissue Matrix is a surgical implant used to support the reconstruction process. The study does not involve randomization, and treatment groups are determined by surgical approach. The reconstruction is performed in two stages over the course of the study. During the study, researchers will monitor participants for major complications related to breast reconstruction occurring up to 18 months after the first surgery stage. They will also evaluate changes in satisfaction with breasts using the BREAST-Q questionnaire up to 18 months after the second stage. Additionally, adverse events will be tracked for up to approximately 36 months. Participants will have regular assessments to ensure safety and effectiveness of the reconstruction process throughout the study duration.

Researchers are evaluating the safety and effectiveness of Phentolamine Ophthalmic Solution in adults who have previously undergone keratorefractive surgery and experience reduced visual acuity in low light conditions. This phase 3 trial compares the effects of Phentolamine Ophthalmic Solution to a placebo to determine if the drug improves night vision. The study focuses on participants who report symptoms like glare, halos, or starbursts that began within two months after their surgery. Participants will be randomly assigned to receive either 0.75% Phentolamine Ophthalmic Solution or a placebo, both administered once daily for two weeks. During this period, participants will visit the clinic weekly for checkups and testing. They will also keep a daily diary to record when they apply the study medication each evening. Throughout the study, participants will undergo vision tests to measure changes in visual acuity under mesopic (low light) conditions. The main outcome is the percentage of participants who gain at least 15 letters (equivalent to 3 lines) improvement in vision at day 15 compared to the start. Researchers will monitor safety and collect data on any side effects. Participation involves regular clinic visits, vision assessments, and adherence tracking over the two-week treatment period.

Researchers are evaluating the safety and effectiveness of a new device called the Reia System, which includes the Reia pessary and applicator, compared to standard pessary care for women with stage II-IV pelvic organ prolapse (POP). This study involves women who have not used a pessary before, are symptomatic, and have chosen vaginal pessary treatment. The trial is randomized and controlled, aiming to assess satisfaction and other outcomes over six months among 200 participants from multiple specialized urogynecology and reconstructive pelvic surgery centers. Participants will be randomly assigned to use either the Reia System or standard pessary care, which includes Gellhorn or ring pessaries with or without support but without a knob. The study involves a total of four visits over six months, during which participants will use their assigned pessary device at home. Researchers will compare the ease of use, number of self-management events like insertion and removal, rates of successful fitting and refitting, and any adverse events between the two groups. Throughout the study, participants will complete validated surveys to assess quality of life, satisfaction with treatment, and the importance and difficulty of self-managing their pessary. Outcomes will be measured at six months, including safety monitoring and tracking of any adverse events or complications. The study aims to understand how well the devices work, how satisfied participants feel, and how the ability to self-manage impacts their experience during this six-month period.

Researchers are conducting a global two-part, proof-of-concept Phase 2 study to evaluate BLU-808, a wild type KIT inhibitor, in adults with Chronic Inducible Urticaria (CIndU) or Chronic Spontaneous Urticaria (CSU). The study focuses on assessing the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808 in these participants. Both conditions involve chronic urticaria that has not responded adequately to second generation H1-antihistamines for at least three months prior to the study. Participants will receive either BLU-808 or a placebo, both given orally, to compare effects. The study has two parts, Part A for those with CIndU and Part B for those with CSU. Treatment and evaluations will be conducted over a defined period with monitoring for any treatment-emergent adverse events from Day 1 through Week 16. During the study, participants will be closely monitored for safety and treatment responses. Researchers will record any adverse events and assess clinical outcomes related to the skin conditions. The study aims to gather comprehensive data on how the drug behaves in the body and its effects, with a focus on participant safety and treatment tolerability throughout the 16-week period.